Physician profile
Brian Schlick
NPI 1063946945
$7,321.02
in general payments reported to CMS, 2019-2025
42 companies · $2,122 in 2025
The $2,122 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $233 · 2022: $246 · 2023: $538 · 2024: $4,183 · 2025: $2,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,679 · Consulting Fee: $1,950 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,679.10 |
| Consulting Fee | $1,950.00 |
| Education | $212.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $1,157.15 | 2024-2025 | |
| Beigene USA, INC. | $762.53 | 2024 | Brukinsa, Tevimbra |
| Merck Sharp & Dohme LLC | $606.57 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Alexion Pharmaceuticals, INC. | $395.92 | 2021-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $373.67 | 2024-2025 | Lynparza, Tagrisso, Imfinzi |
| Genzyme Corporation | $268.63 | 2021-2024 | |
| Jazz Pharmaceuticals INC. | $244.38 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $243.37 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $189.62 | 2022-2025 | Opdivo, Opdualag |
| Pfizer INC. | $182.77 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $172.13 | 2023-2025 | Libtayo |
| Janssen Biotech, INC. | $166.76 | 2024-2025 | Darzalex, Tecvayli, Rybrevant |
| Celgene Corporation | $162.50 | 2023-2025 | Reblozyl, Opdivo, Pomalyst |
| Astellas Pharma US INC | $160.20 | 2022-2024 | Vyloy |
| Genmab U.S., INC. | $159.72 | 2024 | Epkinly |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $149.56 | 2023-2025 | Iclusig, Ninlaro, Alunbrig |
| Lilly USA, LLC | $142.50 | 2023-2025 | Retevmo, Jaypirca, Verzenio |
| Morphosys, US INC. | $139.98 | 2023 | Monjuvi |
| Eisai INC. | $136.97 | 2023-2025 | |
| Gilead Sciences, INC. | $136.47 | 2024 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $125.34 | 2024-2025 | |
| Adaptive Biotechnologies Corporation | $117.94 | 2024 | Clonoseq |
| Pharmacosmos Therapeutics INC. | $113.62 | 2025 | Cosela, Monoferric |
| Medtronic, INC. | $105.41 | 2024 | Arcpoint |
| Incyte Corporation | $103.48 | 2024 | Monjuvi, Pemazyre, Jakafi |
| Seagen INC. | $92.99 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.57 | 2024-2025 | |
| Array Biopharma INC | $87.30 | 2024-2025 | Xalkori, Mektovi, Lorbrena |
| Daiichi Sankyo INC. | $83.52 | 2024 | Enhertu |
| Glaxosmithkline, LLC. | $73.37 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Pharmaessentia USA Corporation | $60.16 | 2024-2025 | Besremi |
| Genentech USA, INC. | $59.11 | 2024-2025 | Venclexta, Perjeta, Phesgo |
| Abbvie INC. | $48.96 | 2024-2025 | |
| Emd Serono, INC. | $40.25 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $32.06 | 2025 | Romvimza, Qinlock |
| Rigel Pharmaceuticals, INC. | $31.08 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Sun Pharmaceutical Industries INC. | $22.08 | 2024 | |
| Tersera Therapeutics LLC | $19.43 | 2025 | Zoladex |
| Stemline Therapeutics INC. | $17.72 | 2024 | Orserdu |
| Agios Pharmaceuticals, INC. | $14.99 | 2024 | |
| Beone Medicines USA, INC. | $14.43 | 2025 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.81 | 2024 | Gilotrif |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Schlick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.